Deals
Going private could give Recordati strategic flexibility and a stable source of capital, according to CVC Capital Partners and Groupe Bruxelles Lambert, which are offering to take the Italian pharma private for a 13% premium.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Medtronic plc today announced the pricing terms of the previously-announced cash tender offers by its wholly-owned subsidiaries, Medtronic, Inc. and Covidien International Finance S.A. (“CIFSA” and, together with Medtronic, Inc., the “Offerors”), for any and all (the “Any and All Tender Offers”) of the $3.1 billion in aggregate principal amount of the outstanding Notes
No employees of GTx are expected to remain with the new company once the merger is complete. Oncternal will begin to trade on the Nasdaq under the ticker symbol ONCT.
Medtronic plc today announced that, pursuant to the previously-announced cash tender offers
Coming off its record-breaking initial public offering (IPO) in December, where it raised $604.3 million, Moderna released its fourth-quarter financials, outlining an ambitious company buzzing with activity.
Bristol-Myers Squibb announced its bid to acquire Celgene on January 3, 2019. However, the deal hit a snag. Bristol-Myers Squibb is now fighting back, making efforts to sell the deal to its shareholders.
Medtronic Global Holdings S.C.A., has priced an offering of €500,000,000 principal amount of floating rate senior notes due 2021, €1,500,000,000 principal amount of 0% senior notes due 2021, €1,500,000,000 principal amount of 0.375% senior notes due 2023, €1,500,000,000 principal amount of 1.125% senior notes due 2027, €1,000,000,000 principal amount of 1.625% senior notes due 2031, and €1,000,000,000 principal amount of 2.250% senior notes due 2039.
Medtronic plc announced the upsizing of the previously-announced cash tender offers by its wholly-owned subsidiaries, Medtronic, Inc.
Bristol-Myers Squibb and Celgene Corporation are strongly urging shareholders to submit their proxy votes as quickly as possible whether they plan to attend the April 12, 2019 Special Meeting or not. The meeting is when the official vote on whether Bristol-Myers Squibb will buy Celgene will take place.
San Diego-based Pacira Pharmaceuticals, a specialty pharmaceutical company, plunked down $220 million to acquire medical device company Myoscience and its non-opioid pain treatment system iovera.
As Purdue Pharma grapples with multiple lawsuits over its OxyContin pain killer, there are reports that the drugmaker is exploring bankruptcy as a legal defense mechanism.